Outbreak Brief #23: Mpox in African Union Member States

Date of Issue: 21 December 2022

1,176 confirmed cases, 219 deaths in AU MS

Data sources: US CDC, WHO, and AU Member State Ministries of Health

Global Update (non-endemic countries): As of 19 Dec 2022, 83,026 confirmed cases of mpox and 269 deaths were reported from 110 countries/territories globally. The countries reporting the majority of cases are mainly in Europe and the Americas.

Africa update (endemic and non-endemic countries): Since the beginning of 2022, the continent has reported 1,176 confirmed cases and 219 deaths (CFR: 18.6%) of mpox from eight endemic Africa Union (AU) Member States (MS): Benin (3 confirmed cases; 0 confirmed deaths), Cameroon (18; 3), CAR (8; 2), Congo (5; 3), Democratic Republic of Congo (DRC) (257; 198), Ghana (107; 4), Liberia (3; 0), Nigeria (704; 7) and five non-endemic MS: Egypt (4; 0), Morocco (3; 0), Mozambique (1; 1), South Africa (5; 0) and Sudan (18; 1). This week, 45 new confirmed cases and ten new deaths of mpox were reported from DRC (0 cases; 10 deaths) and Nigeria (45; 0).

DRC: Since the last update (16 December 2022), the MoH reported no new confirmed cases and 10 deaths of mpox for epidemiology week 49. This is a 43% increase in the number of new deaths compared to last update. Cumulatively, 277 confirmed cases and 198 deaths (CFR: 71.4%) were reported from 23 of the 26 provinces in the country.

Nigeria: Since the last report, (9 December 2022), NCDC reported 45 new confirmed cases and no new death from monkeypox for epidemiology week 50. This is a 29% increase in the number of new confirmed cases compared to the last report. Cumulatively, 704 confirmed and seven deaths (CFR: 1%) of monkeypox were reported from 36 states and the federal capital.

1 Global case and death numbers are inclusive of numbers being reported in Africa.
3 Cameroon, the Central African Republic, the Democratic Republic of the Congo, Gabon, Ghana, Côte d’Ivoire, Liberia, Nigeria, the Republic of the Congo, and Sierra Leone
Figure 1. New confirmed mpox cases reported by epidemiological week in AU MS since January 2022

The majority of AU MS reporting cases are from the central and western Africa regions with DRC, Ghana and Nigeria accounting for 94% of all confirmed cases reported (Table 1). Most cases were reported after the week of 21 July and this could be a result of enhanced surveillance in MS (Figure 1).

---

4 The high numbers of confirmed cases reported from DRC in week 15 July is likely the result of batch reporting.
Table 1. Cumulative confirmed mpox cases and deaths reported from African Union Member States in 2022 - as of 20 December 2022.

<table>
<thead>
<tr>
<th>Country</th>
<th>Total confirmed cases (new)</th>
<th>Total confirmed deaths (new)</th>
<th>CFR\textsuperscript{5}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benin</td>
<td>3 (0)</td>
<td>0 (0)</td>
<td>0%</td>
</tr>
<tr>
<td>Cameroon</td>
<td>18 (0)</td>
<td>3 (0)</td>
<td>17%</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>8 (0)</td>
<td>2 (0)</td>
<td>25%</td>
</tr>
<tr>
<td>Congo Republic</td>
<td>5 (0)</td>
<td>3 (0)</td>
<td>60%</td>
</tr>
<tr>
<td>Democratic Republic of Congo</td>
<td>277 (0)</td>
<td>198\textsuperscript{6} (10)</td>
<td>72%</td>
</tr>
<tr>
<td>Ghana</td>
<td>107 (0)</td>
<td>4 (0)</td>
<td>4%</td>
</tr>
<tr>
<td>Egypt</td>
<td>4 (0)</td>
<td>0 (0)</td>
<td>0%</td>
</tr>
<tr>
<td>Liberia</td>
<td>3 (0)</td>
<td>0 (0)</td>
<td>0%</td>
</tr>
<tr>
<td>Morocco</td>
<td>3 (0)</td>
<td>0 (0)</td>
<td>0%</td>
</tr>
<tr>
<td>Mozambique</td>
<td>1 (0)</td>
<td>1 (0)</td>
<td>100%</td>
</tr>
<tr>
<td>Nigeria</td>
<td>704 (45)</td>
<td>7 (0)</td>
<td>1%</td>
</tr>
<tr>
<td>Sudan</td>
<td>18 (0)</td>
<td>1 (0)</td>
<td>5%</td>
</tr>
<tr>
<td>South Africa</td>
<td>5 (0)</td>
<td>0 (0)</td>
<td>0%</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>1,176 (45)</strong></td>
<td><strong>219 (10)</strong></td>
<td><strong>19%</strong></td>
</tr>
</tbody>
</table>

Event Geoscope and Risk Assessment Levels

Africa Centres for Disease Control and Prevention (Africa CDC) conducted a preliminary assessment of the geographic scope (geoscope) and risk level for the mpox events being reported for Africa and globally. Given that this outbreak is currently affecting multiple countries both on and outside of the continent, the geoscope assessment is high. If additional

\textsuperscript{5} Case fatality ratio is the proportion of confirmed deaths over confirmed cases.

\textsuperscript{6} Africa CDC cannot ascertain that all deaths reported from DRC are laboratory confirmed. Africa CDC is working with the DRC to clarify this data.
AU MS report disease linked to this outbreak, we will reassess and elevate accordingly. For the risk assessment level, we looked at the following criteria: morbidity and mortality of the disease, probability to spread within and to other AU MS, and the availability of effective treatments, vaccines, or other control measures. We have listed the risk level as moderate given that mpox is not an easily transmissible, self-limiting disease with low mortality, which lacks effective treatment for those infected. We are closely monitoring the situation and we will reevaluate the risk periodically.

**Member State Response Activities**

**DRC:** The MoH continues to conduct active case search in the affected communities.

**Nigeria:** NCDC continues to strengthen surveillance at the national and sub-national levels.

**New Africa CDC Response Activities**

- On 8 August 2022, the Africa CDC Emergency Operations Centre (EOC) was activated to support preparedness and response efforts of African Union Member States, in close collaboration with relevant partners
- The Africa CDC continues to provide support to AU MS with laboratory test kits on request.
- The Africa CDC continues to engage with Ministries of Health in Member States reporting cases to provide support as requested
- Africa CDC engaged the government of the Republic of Korea, through Korea Disease Control and Prevention Agency (KDCA) to ensure access to mpox vaccines. A commitment to donate 50,000 doses was made during the 7th Global Health Security Agenda meeting held in the Republic of Korea in Seoul from 28-30 November 2022.

**Recommendations for AU Member States**

Member States are advised to:

- Establish laboratory diagnostic and genomic sequencing capacity for orthopoxviruses, including mpox.
- Establish and/or strengthen existing mpox surveillance efforts.
- Develop and distribute both general and tailored risk communication messages for the community at large as well as specific populations currently impacted and at risk (e.g., sex-workers, immunocompromised individuals, children).
- Strengthen knowledge of mpox clinical management and infection prevention control measures.
- Report new cases of mpox as part of the current multi-country outbreak to Africa CDC ([AfricaCDCEBS@Africa-Union.org](mailto:AfricaCDCEBS@Africa-Union.org))
- Member States that need support from Africa CDC should submit requests for support to the Director Africa CDC ([AfricaCDCEBS@Africa-Union.org](mailto:AfricaCDCEBS@Africa-Union.org))

The general public is advised to:

---

● Seek medical attention if you experience any mpox-like symptoms (e.g., develop rash with or without prior symptoms of fever, swollen lymph nodes, body aches, and weakness), especially if you have been in contact with a positive case
● Practice effective hand hygiene by washing hands with soap and water or using an alcohol-based hand sanitizer, especially after contact with any infected animal or human
● Avoid contact with animals that could harbor the virus, including animals that are sick or found dead in areas where mpox occurs
● Avoid contact with any potentially contaminated material, such as clothes and bedding, with which animals with mpox have been in contact with
● If deemed a close contact of a mpox case, individuals should self-monitor for the development of symptoms up to 21 days from the last exposure to a case
● If you are infected with mpox, adhere to recommended isolation protocols prescribed by your medical provider to minimize transmission to others, including pets and other animals that may be susceptible to mpox infection

References
1. European Centres for Disease Prevention and Control (ECDC) - Risk assessment: Monkeypox multi-country outbreak (23 May 22)
3. US CDC - Information for the clinical management of monkeypox
4. US CDC - 2022 Monkeypox Outbreak Global Map | Monkeypox | Poxvirus | CDC
5. US CDC - Monkeypox: Get the Facts
6. WHO - Monkeypox factsheet
7. WHO - Multi-country monkeypox outbreak in non-endemic countries
8. WHO - Laboratory testing for the monkeypox virus: Interim guidance
9. WHO - Meeting of the international health regulations (2005) emergency committee regarding the multi-country monkeypox outbreak
10. WHO - Director-General's statement on the report of the meeting of the IHR 2005 emergency committee regarding the multi-country monkeypox outbreak
11. WHO recommends new name for monkeypox disease
12. The Republic of Korea to Donate First Batch of Mpox Vaccine to Africa